Measurement of problem behaviour during medication evaluations.

Ahlborn et al. (2008) wrote a narrative review. They looked at ways to track problem behavior during medication checks for people with intellectual disability.

The authors compared rating scales, direct observation, and team reports. They asked which tools best show if a drug helps or harms.

No single tool tells the whole story. The review says combine direct observation with socially valid rating scales.

Medical, behavioral, and care teams must share data. When teams talk, side effects and gains are caught early.

Singh et al. (1991) set an early map. They also urged multi-method batteries—history, interviews, scales, and brief tests—for the same group.

Robinson et al. (2011) extends this work. They warn that classic drug RCTs can withhold care. Instead, they push single-case or adaptive designs when meds and behavior plans mix.

Thurm et al. (2020) and Halladay (2025) update the toolbox. They show classic IQ and adaptive scales often miss change. They recommend Vineland-3 and person-ability scores for clearer pictures.

Hassiotis et al. (2022) add a caution. Their meta-analysis finds wide gaps between stats and stakeholder views on what counts as a “real” change on the ABC-I. Pick your cutoff carefully.

You now have a shopping list, not just one tool. Pair brief direct observation with a scale like ABC-I or Vineland-3. Plot data weekly and share graphs with the prescriber. If the team sees no clear dip in problem behavior after a dose change, you have evidence to adjust or stop. This keeps clients safe and saves months of guesswork.